Lord Hunt of Kings Heath – 2015 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Lord Hunt of Kings Heath on 2015-11-19.
To ask Her Majesty’s Government what assessment they have made of the effectiveness of bevacizumab in the treatment of age-related macular degeneration.
Lord Prior of Brampton
No assessment by the Government has been made on the effectiveness of bevacizumab (Avastin) in the treatment of wet age-related macular degeneration (AMD) as there are two other effective, licensed treatments for wet AMD which have been recommended by the National Institute for Health and Care Excellence. Bevacizumab is not licensed for use in the treatment of wet AMD.
